Study of the Response and Cardiorespiratory Endurance in Early RA Patients Treated With Tocilizumab or Methotrexate
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
To measure the CRE by a work capacity index obtained in a submaximal testing (W65%/kg) in
early RA patients treated with tocilizumab compared to Methotrexate alone.
The secondary endpoints : analyze the clinical efficacy of Tocilizumab in this population and
correlate the CRE response with other marker (CRP, Hb, DAS, HAQ) and evaluate the safety
profile of Tocilizumab.